Research Article
Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study
Table 4
Response to treatment in AIH features after 3, 6, and 12 months of therapy.
| |||||||||||||||||||||||||||||||||||
Twenty-one patients were treated for more than 12 months in total. #Eleven patients were treated for more than 12 months in the UDCA-only group. ##Ten patients were treated for more than 12 months in the UDCA+IS group. |